An international team co-led by the Institute for Bioengineering of Catalonia (IBEC) and the West China Hospital Sichuan University (WCHSU) was able to reverse Alzheimer’s in mice after only 3 injections with nanoparticles.   

The innovative approach to treating the disease focuses on restoring the normal function of the vasculature, rather than acting on neurons or other brain cells, as has usually been done until now.

This achievement, published in the Signal Transduction and Targeted Therapy Journal, is a promising step towards an effective treatment for Alzheimer’s disease.

The Alzheimer’s Association has selected Gladstone’s Katerina Akassoglou, PhD, as a 2025 recipient of the Zenith Fellows Award, an international prize given annually to scientists making substantial contributions to the field of Alzheimer’s research. A senior investigator at Gladstone Institutes and director of the Gladstone-UCSF Center for Neurovascular Brain Immunology, Akassoglou has pioneered research into interactions between the brain, blood vessels, and immune system—and has shown how those interactions drive the development and progression of Alzheimer’s and other neurodegenerative diseases.